In a report released yesterday, Alethia Young from Cantor Fitzgerald reiterated a Buy rating on TG Therapeutics (TGTX), with a price target of $17. The company’s shares closed on Friday at $7.56.
Young commented:
“: We reiterate our Overweight and $17 PT. On the 1Q call, TG discussed recent pipeline progress, including the interim data for umbralisib in marginal zone lymphoma (MZL) that were presented at AACR last month and potential updates over the rest of 2019 and early 2020. After positive interim data for umbralisib in MZL, another major milestone will be discussing recent positive MZL data with the FDA. The final MZL data are to be presented toward the end of 2019 (we think potentially at the meantime, the company plans to present an update at ASCO and meet with the FDA to discuss accelerated approval.”
According to TipRanks.com, Young is a 4-star analyst with an average return of 5.9% and a 45.5% success rate. Young covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Spectrum Pharmaceuticals, and Vertex Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for TG Therapeutics with a $17.33 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $16 and a one-year low of $3.32. Currently, TG Therapeutics has an average volume of 2.35M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib.
